SIRPant-M

SIRPant-M is an autologous cell therapy composed of patient-derived macrophages that are activated ex vivo using a proprietary cytokine cocktail (PhagoAct) to reduce the expression and activity of signal regulatory protein alpha (SIRPα). This non-genetically modified product is designed to enhance the ability of macrophages to recognize and eliminate cancer cells by overcoming inhibitory signals in the tumor microenvironment. The therapy induces a polyclonal immune response targeting tumor-specific neoantigens, stimulating both cytotoxic T cells and antibody production against cancer cells. It also transforms the tumor microenvironment into a pro-inflammatory state, reduces immunosuppressive factors, and promotes durable immune memory against relapse. SIRPant-M is being developed for hematologic malignancies such as T-cell lymphoma and non-Hodgkin lymphoma (NHL), as well as solid tumors including head and neck cancers. The product can be administered alone or in combination with other immunostimulatory modalities like radiotherapy or immune checkpoint inhibitors[1][4][5][6][10].

Brand names

SIRPant-M

Other names

SIRPant-MSI-101SI101SI 101